Mast Therapeutics has announced that it will stop its development program for vepoloxamer and will devote its resources to development of AIR001 sodium nitrite inhalation solution for patients with heart failure with preserved ejection fraction (HFpEF) and for pulmonary arterial hypertension (PAH).
The company currently has 3 separate Phase 2 clinical trials of AIR001 underway, including the INDIE-HFpEF trial (NCT02742129) which was initiated in August 2016 and which is sponsored by the Duke Clinical Research Institute.
In February 2016, the company announced positive results from a Phase 2a clinical study of AIR001 in HFpEF patients conducted at the Mayo Clinic. Detailed results have been published in Circulation Research.
Mast Therapeutics CEO Brian M. Culley commented, “Following a critical review of our pipeline and opportunities we have determined that a focus on AIR001 will provide for a strong foundation from which we will seek to return value to our stockholders. However, these decisions likely will have a significant impact on our talented team members and I want to personally thank those who may be affected for their hard work, dedication and contributions to the vepoloxamer program.”
Read the Mast Therapeutics press release.
